Novo Nordisk (NVO) has started a round of job cuts in the U.S. as the weight loss drugmaker continues its plans to eliminate about 9,000 roles globally under a major restructuring drive, Reuters reported on Wednesday, citing an email and two sources familiar with the matter.
The layoffs began on Tuesday, with affected staff members expected to be notified this week and the next. Job cuts will continue until late next week, impacting several departments, including HR, marketing & sales, clinical development, legal, ethics, and compliance, according to an email schedule.
Soon after assuming office in August, Novo’s (NVO) new CEO Mike Doustdar started a company-wide reorganization as the maker of the obesity drug Wegovy plays catch-up to its U.S. rival Eli Lilly (LLY) in the booming market for weight loss drugs.
Last week, Bloomberg News reported that the company is closing its cell therapy unit as part of the initiative, impacting all 250 employees there.